2 / 27
Llovet J. & Hernandez-Gea V. Clin Cancer Res. 2014 Apr 15;20(8):2072-9
1L systemic therapies evaluated in Phase 3 clinical trials
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
ASIA-
PACIFIC
Sorafenib
SHARP
Sorafenib
Sorafenib’s
Approval
LIGHT
Linifanib
REFLECT
Lenvatinib
Lenvatinib’s
Approval
BRISK - FL
Brivanib
SEARCH
Erlotinib +
Sorafenib
SUN
Sunitinib
All
4 trials
reported
negative results